Cagrilintide is a long-acting analogue of the pancreatic hormone amylin under investigation as a weight-regulation agent, most prominently in fixed combination with semaglutide. This article reviews what the peptide is, how amylin signalling is understood in experimental models, and what the human trial record does and does not yet establish.

What cagrilintide is

Amylin, also called islet amyloid polypeptide, is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells that contributes to the control of energy homeostasis and body weight.¹ Native amylin is short-lived and aggregation-prone, which limits its usefulness as a research tool for chronic-exposure studies. Cagrilintide is a synthetic analogue designed to overcome those liabilities: the peptide backbone is modified to resist aggregation and is acylated with a fatty-diacid side chain that promotes reversible albumin binding, extending its circulating half-life to a range compatible with once-weekly subcutaneous administration.²

This design lineage distinguishes cagrilintide from earlier amylin-receptor agonists such as pramlintide, which required multiple daily injections, and from salmon calcitonin, a non-selective agonist historically used to probe the same receptor system. In the medicinal-chemistry work describing the molecule, investigators reported that structural stabilisation and lipidation were the two levers used to convert a labile endogenous hormone into a long-acting research candidate.² The result is a peptide that, in the words of one review, is being developed less as a stand-alone agent than as one half of a two-hormone strategy.³

How amylin signalling is understood

Amylin does not act through a single dedicated receptor. Instead, it engages a family of heterodimeric receptors formed when the calcitonin core receptor (CTR) pairs with one of several receptor-activity-modifying proteins (RAMPs). The CTR–RAMP1 and CTR–RAMP3 combinations are commonly designated the amylin receptors AMY1R and AMY3R.⁴ These receptors are enriched in the area postrema, a circumventricular structure in the caudal hindbrain that lies outside the blood–brain barrier and is well positioned to sense circulating peptides, with downstream relays to the nucleus tractus solitarius (NTS) and the lateral parabrachial nucleus (LPBN).⁵

The causal role of this circuit has been probed directly in rodents. In one proof-of-concept study, viral depletion of calcitonin receptors in the area postrema and NTS blunted the neuronal-activation and food-intake responses that normally follow amylin or salmon-calcitonin administration, supporting the view that hindbrain CTR signalling is required for amylin's satiation effect in that model.⁵ Reviews of long-acting amylin analogues have summarised this mechanism as activity at calcitonin and amylin receptors in the area postrema that contributes to the control of energy homeostasis, while cautioning that much of the receptor-level detail derives from animal and in-vitro systems rather than human tissue.¹

Why the pathway complements GLP-1 agonists

The research interest in cagrilintide is inseparable from the pathway it does not use. GLP-1 receptor agonists such as semaglutide act largely through GLP-1 receptors in the hypothalamus and slow gastric emptying, whereas amylin analogues act through the CTR–RAMP receptors described above.³ Because the two systems converge on appetite regulation through different upstream receptors, combining them has been proposed as an additive strategy rather than a redundant one. A narrative review of the combination framed the amylin and GLP-1 mechanisms as "separate, but related" routes to appetite reduction that appear additive when engaged together.⁶

This logic underlies the fixed combination of cagrilintide and semaglutide, referred to in the literature as CagriSema.⁷ It also situates cagrilintide within a broader wave of multi-target metabolic peptides, alongside dual and triple agonists such as tirzepatide and retatrutide, which pursue the same goal of layering complementary receptor mechanisms.⁸ For research purposes, the practical consequence is that cagrilintide is frequently studied not in isolation but as a component of a defined two-peptide system, which complicates attribution of any single observation to the amylin analogue alone.

What the clinical trials report

Cagrilintide has moved through early- and late-phase human trials, and the reported figures should be read against the specific populations, durations, and comparators of each study rather than generalised.

The phase 2 dose-finding trial randomised adults with overweight or obesity to once-weekly cagrilintide across five doses versus liraglutide 3.0 mg and placebo over 26 weeks. According to the trial-product estimand, mean body-weight reductions ranged from about 6.0% to 10.8% across cagrilintide doses versus 3.0% with placebo, with the 4.5 mg dose exceeding liraglutide 3.0 mg.⁹ An earlier phase 1b study co-administering cagrilintide with semaglutide 2.4 mg over roughly 20 weeks reported mean body-weight reductions in the 15–17% range at the higher cagrilintide doses versus pooled placebo, in a small healthy-volunteer cohort.¹⁰

The most fully powered dataset comes from the phase 3a REDEFINE 2 trial in adults with overweight or obesity and type 2 diabetes. Over 68 weeks, once-weekly cagrilintide–semaglutide (2.4 mg each) produced an estimated mean body-weight change of −13.7% versus −3.4% with placebo, and 73.5% of the combination group reached a glycated-haemoglobin level of 6.5% or lower versus 15.9% with placebo.⁷ A separate phase 3a trial in an East Asian population, REDEFINE 5, compared the combination against semaglutide 2.4 mg alone and reported an estimated mean change of −18.4% versus −11.9% over 68 weeks.¹¹ The table below summarises these anchor studies.

Two cautions follow from this record. First, the largest effect sizes come from combination regimens, so they cannot be attributed to cagrilintide as an isolated agent. Second, populations differ across trials — diabetes status, ethnicity, and baseline BMI all vary — which limits direct cross-study comparison. The trials establish a dose-dependent signal and a combination signal; they do not establish head-to-head monotherapy superiority across all settings.

Body composition: what the evidence supports

A frequently repeated claim is that cagrilintide reduces fat mass while preserving lean mass. The mechanistic rationale is reasonable: amylin-receptor agonism acts on satiety circuits rather than on muscle-catabolic pathways, and reviews of the amylin system describe its effects on body weight as arising from central energy-homeostasis signalling.¹ Salmon calcitonin, the older non-selective comparator, has been contrasted with selective amylin analogues in mechanistic discussions of receptor kinetics and specificity.⁴

What the current human record does not yet provide is a robust, consistent set of body-composition endpoints (for example, DXA-measured fat-versus-lean partitioning) demonstrating lean-mass preservation as a primary, replicated outcome specific to cagrilintide. The claim is best described as mechanistically plausible and preclinically supported rather than definitively established in humans. Reviews of long-acting amylin analogues explicitly note that more studies are needed to characterise long-term effects in relevant populations.¹ For laboratory researchers, body-composition partitioning therefore remains an open and legitimate question rather than a settled fact.

Tolerability signals and open questions

Across the trials, the most frequently reported adverse events were gastrointestinal — nausea, constipation, and diarrhoea — consistent with the broader class of appetite-regulating peptides. In the phase 2 study, gastrointestinal events were more common with cagrilintide than placebo, and in the REDEFINE 2 combination trial gastrointestinal events were reported by roughly 72% of the combination group versus about 34% of placebo, most described as transient and mild to moderate.⁷⁹ These are trial-reported safety observations in supervised clinical settings, not a general safety characterisation, and they do not translate into any statement about use outside those settings.

Several questions remain genuinely open in the literature. The durability of effect beyond the trial windows, the relative contribution of cagrilintide within the combination, dose-response at the receptor level in human tissue, and any longer-term metabolic or cardiovascular endpoints are all areas where published human data are limited or absent. Contemporary reviews place cagrilintide among "molecules under development" whose long-term efficacy, safety, and cost-effectiveness will need further evidence before their position is clear.¹² That framing — promising signal, incomplete picture — is the honest state of the field.

Regulatory status and research framing

As of 2026, cagrilintide is an investigational compound. Neither cagrilintide alone nor the cagrilintide–semaglutide combination is an approved medicine in the United States, and the material described here has no approved therapeutic indication.³⁶ References to weight change, glycaemic measures, or receptor activity in this article describe outcomes measured in clinical trials or experimental models; they are not statements about outcomes in any individual and are not medical guidance.

Within a research context, cagrilintide is useful precisely because its mechanism is distinct and its combination behaviour is non-trivial: it offers a defined amylin-receptor tool for studying satiety circuits, receptor pharmacology, and additive signalling alongside GLP-1 and dual-agonist peptides. Qovigen supplies cagrilintide, semaglutide, and related peptides as high-purity, batch-tested materials for in-vitro and laboratory investigation, so that questions of the kind raised above can be examined under controlled conditions.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.